Publications by authors named "M Courant"
Background: Congenital CMV infection is the leading cause of neonatal neurological deficit. We herein studied in vitro and ex vivo the potential of the hyperimmune globulin Cytotect CP (Biotest, Germany) for congenital infection prevention and treatment.
Methods: In vitro neutralization assays were conducted in fibroblasts and retinal epithelial cells on the CMV strains TB40/E and VHL/E to determine the 50% and 90% neutralizing doses (ND50 and ND90).
Article Synopsis
- Cytomegalovirus (CMV) is a significant cause of complications and mortality post-transplantation, and specific T cell responses are crucial for recovery.
- The study focuses on a particular subgroup of T cells, Vγ9negVδ2pos, which are distinct from other T cell types and play a role in the immune response to CMV.
- These Vγ9negVδ2pos T cells show potential for use as an immune marker to gauge the severity of CMV disease in kidney transplant patients.
Background: Renal impairment (RI), a severe complication in multiple myeloma (MM), is considered as a poor prognostic factor. Patient survival has increased with the use of novel drugs and autologous stem-cell transplantation (ASCT). However, specific evolution of the incidence of RI in MM and its impact on prognosis remain unclear.
View Article and Find Full Text PDFBackground: Pathogenicity of donor-specific antibodies (DSAs) can be assessed using the single-antigen flow beads (SAFB) assays through mean fluorescence intensity (MFI) with or without serum ethylenediaminetetraacetic acid (EDTA) treatment, measurement of C1q or C3d binding and/or their intragraft detection [graft-bound donor-specific antibody (gDSA)]. We aimed to investigate which of these markers best associates with antibody-mediated rejection (ABMR) and kidney allograft loss at the time of a for-cause biopsy.
Methods: This retrospective, single-centre study included 77 kidney transplant recipients who underwent a for-cause biopsy between December 2004 and July 2013.